
Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:TSRO
CUSIP88156910
Phone339-970-0900
Debt
Debt-to-Equity Ratio1.75%
Current Ratio4.74%
Quick Ratio4.39%
Price-To-Earnings
Trailing P/E Ratio-5.67
Forward P/E Ratio-5.58
P/E GrowthN/A
Sales & Book Value
Annual Sales$223.33 million
Price / Sales12.92
Cash FlowN/A
Price / CashN/A
Book Value$4.58 per share
Price / Book11.50
Profitability
EPS (Most Recent Fiscal Year)($9.17)
Net Income$-496,120,000.00
Net Margins-222.15%
Return on Equity-126.44%
Return on Assets-67.17%
Miscellaneous
Employees715
Outstanding Shares54,800,000